We are analyzing https://link.springer.com/article/10.1186/bcr2347.

Title:
The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition | Breast Cancer Research
Description:
Introduction Notch is a family of transmembrane protein receptors whose activation requires proteolytic cleavage by γ-secretase. Since aberrant Notch signaling can induce mammary carcinomas in transgenic mice and high expression levels of Notch receptors and ligands correlates with overall poor clinical outcomes, inhibiting γ-secretase with small molecules may be a promising approach for breast cancer treatment. Consistent with this hypothesis, two recent papers reported that γ-secretase inhibitor I (GSI I), Z-LLNle-CHO, is toxic to breast cancer cells both in vitro and in vivo. In this study, we compared the activity and cytotoxicity of Z-LLNle-CHO to that of two highly specific GSIs, DAPT and L-685,458 and three structurally unrelated proteasome inhibitors, MG132, lactacystin, and bortezomib in order to study the mechanism underlying the cytotoxicity of Z-LLNle-CHO in breast cancer cells. Methods Three estrogen receptor (ER) positive cell lines, MCF-7, BT474, and T47D, and three ER negative cell lines, SKBR3, MDA-MB-231, and MDA-MB-468, were used in this study. Both SKBR3 and BT474 cells also overexpress HER2/neu. Cytotoxicity was measured by using an MTS cell viability/proliferation assay. Inhibition of γ-secretase activity was measured by both immunoblotting and immunofluorescent microscopy in order to detect active Notch1 intracellular domain. Proteasome inhibition was determined by using a cell-based proteasome activity assay kit, by immunoblotting to detect accumulation of polyubiquitylated protein, and by immunofluorescent microscopy to detect redistribution of cellular ubiquitin. Results We found that blocking γ-secretase activity by DAPT and L-685,458 had no effect on the survival and proliferation of a panel of six breast cancer cell lines while Z-LLNle-CHO could cause cell death even at concentrations that inhibited γ-secretase activity less efficiently. Furthermore, we observed that Z-LLNle-CHO could inhibit proteasome activity and the relative cellular sensitivity of these six breast cancer cell lines to Z-LLNle-CHO was the same as observed for three proteasome inhibitors. Finally, we found that the cell killing effect of Z-LLNle-CHO could be reversed by a chemical that restored the proteasome activity. Conclusions We conclude that the cytotoxicity of Z-LLNle-CHO in breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

zllnlecho, cell, proteasome, cells, cancer, activity, notch, breast, γsecretase, pubmed, article, inhibition, scholar, google, cas, lines, bortezomib, figure, dapt, cytotoxicity, inhibitor, mcf, effect, concentrations, protein, signaling, study, mdamb, edaravone, treated, gsis, effects, growth, treatment, inhibitors, results, antibody, measured, assay, usa, tiron, data, signal, killing, drugs, control, samples, authors, central, inhibit,

Topics {✒️}

z-leu-leu-leu-aldehyde horseradish peroxidase-conjugated anti-rabbit s-phenylglycine t-butyl ester presenilin-1/gamma-secretase cleavage releases z-llnle-cho-induced cell killing pi3k-pkb/akt-dependent pathway cadmium-induced e-cadherin cleavage substrate-targeting gamma-secretase modulators hendzel & joan allalunis-turner z-llnle-cho-induced inhibition presenilin-1-dependent gamma-secretase presenilin-dependent intramembrane cleavage article download pdf fas-ligand-induced apotosis e-cadherin intracellular domain joan allalunis-turner reverse transcription-coupled pcr notch-1 requires p56lck-dependent gamma-secretase induces g2/ free radical scavenging greater γ-secretase activity z-llnle-cho-induced er-positive cell lines blocking γ-secretase activity er-negative cell lines cell-based assay kit flag-tagged n1ext fragment β-amyloid precursor protein inhibiting γ-secretase activity γ-secretase inhibitory activity notch-survivin signaling axis γ-secretase active site enhanced ligand-receptor interaction γ-secretase dual inhibitor sole γ-secretase inhibitor endocrine-resistant breast cancer inhibited γ-secretase activity specific γ-secretase inhibitor γ-secretase inhibition activity plot dose-response curves akt/pkb-mediated signaling gamma-secretase-independent role trastuzumab targets her2/neu anti-flag monoclonal antibody inhibited cell growth/viability bortezomib-induced cell killing anti-ubiquitin monoclonal antibody cell killing/growth inhibition showed dose-dependent cytotoxicity pro-survival signal provided

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition
         description:Notch is a family of transmembrane protein receptors whose activation requires proteolytic cleavage by γ-secretase. Since aberrant Notch signaling can induce mammary carcinomas in transgenic mice and high expression levels of Notch receptors and ligands correlates with overall poor clinical outcomes, inhibiting γ-secretase with small molecules may be a promising approach for breast cancer treatment. Consistent with this hypothesis, two recent papers reported that γ-secretase inhibitor I (GSI I), Z-LLNle-CHO, is toxic to breast cancer cells both in vitro and in vivo. In this study, we compared the activity and cytotoxicity of Z-LLNle-CHO to that of two highly specific GSIs, DAPT and L-685,458 and three structurally unrelated proteasome inhibitors, MG132, lactacystin, and bortezomib in order to study the mechanism underlying the cytotoxicity of Z-LLNle-CHO in breast cancer cells. Three estrogen receptor (ER) positive cell lines, MCF-7, BT474, and T47D, and three ER negative cell lines, SKBR3, MDA-MB-231, and MDA-MB-468, were used in this study. Both SKBR3 and BT474 cells also overexpress HER2/neu. Cytotoxicity was measured by using an MTS cell viability/proliferation assay. Inhibition of γ-secretase activity was measured by both immunoblotting and immunofluorescent microscopy in order to detect active Notch1 intracellular domain. Proteasome inhibition was determined by using a cell-based proteasome activity assay kit, by immunoblotting to detect accumulation of polyubiquitylated protein, and by immunofluorescent microscopy to detect redistribution of cellular ubiquitin. We found that blocking γ-secretase activity by DAPT and L-685,458 had no effect on the survival and proliferation of a panel of six breast cancer cell lines while Z-LLNle-CHO could cause cell death even at concentrations that inhibited γ-secretase activity less efficiently. Furthermore, we observed that Z-LLNle-CHO could inhibit proteasome activity and the relative cellular sensitivity of these six breast cancer cell lines to Z-LLNle-CHO was the same as observed for three proteasome inhibitors. Finally, we found that the cell killing effect of Z-LLNle-CHO could be reversed by a chemical that restored the proteasome activity. We conclude that the cytotoxicity of Z-LLNle-CHO in breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition.
         datePublished:2009-08-06T00:00:00Z
         dateModified:2009-08-06T00:00:00Z
         pageStart:1
         pageEnd:12
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr2347
         keywords:
            Breast Cancer Cell Line
            Bortezomib
            Proteasome Inhibitor
            Proteasome Activity
            DAPT
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig6_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jianxun Han
               affiliation:
                     name:University of Alberta, Cross Cancer Institute
                     address:
                        name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ivy Ma
               affiliation:
                     name:University of Alberta, Cross Cancer Institute
                     address:
                        name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael J Hendzel
               affiliation:
                     name:University of Alberta, Cross Cancer Institute
                     address:
                        name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Joan Allalunis-Turner
               affiliation:
                     name:University of Alberta, Cross Cancer Institute
                     address:
                        name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition
      description:Notch is a family of transmembrane protein receptors whose activation requires proteolytic cleavage by γ-secretase. Since aberrant Notch signaling can induce mammary carcinomas in transgenic mice and high expression levels of Notch receptors and ligands correlates with overall poor clinical outcomes, inhibiting γ-secretase with small molecules may be a promising approach for breast cancer treatment. Consistent with this hypothesis, two recent papers reported that γ-secretase inhibitor I (GSI I), Z-LLNle-CHO, is toxic to breast cancer cells both in vitro and in vivo. In this study, we compared the activity and cytotoxicity of Z-LLNle-CHO to that of two highly specific GSIs, DAPT and L-685,458 and three structurally unrelated proteasome inhibitors, MG132, lactacystin, and bortezomib in order to study the mechanism underlying the cytotoxicity of Z-LLNle-CHO in breast cancer cells. Three estrogen receptor (ER) positive cell lines, MCF-7, BT474, and T47D, and three ER negative cell lines, SKBR3, MDA-MB-231, and MDA-MB-468, were used in this study. Both SKBR3 and BT474 cells also overexpress HER2/neu. Cytotoxicity was measured by using an MTS cell viability/proliferation assay. Inhibition of γ-secretase activity was measured by both immunoblotting and immunofluorescent microscopy in order to detect active Notch1 intracellular domain. Proteasome inhibition was determined by using a cell-based proteasome activity assay kit, by immunoblotting to detect accumulation of polyubiquitylated protein, and by immunofluorescent microscopy to detect redistribution of cellular ubiquitin. We found that blocking γ-secretase activity by DAPT and L-685,458 had no effect on the survival and proliferation of a panel of six breast cancer cell lines while Z-LLNle-CHO could cause cell death even at concentrations that inhibited γ-secretase activity less efficiently. Furthermore, we observed that Z-LLNle-CHO could inhibit proteasome activity and the relative cellular sensitivity of these six breast cancer cell lines to Z-LLNle-CHO was the same as observed for three proteasome inhibitors. Finally, we found that the cell killing effect of Z-LLNle-CHO could be reversed by a chemical that restored the proteasome activity. We conclude that the cytotoxicity of Z-LLNle-CHO in breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition.
      datePublished:2009-08-06T00:00:00Z
      dateModified:2009-08-06T00:00:00Z
      pageStart:1
      pageEnd:12
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr2347
      keywords:
         Breast Cancer Cell Line
         Bortezomib
         Proteasome Inhibitor
         Proteasome Activity
         DAPT
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2347/MediaObjects/13058_2009_2311_Fig6_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jianxun Han
            affiliation:
                  name:University of Alberta, Cross Cancer Institute
                  address:
                     name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ivy Ma
            affiliation:
                  name:University of Alberta, Cross Cancer Institute
                  address:
                     name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael J Hendzel
            affiliation:
                  name:University of Alberta, Cross Cancer Institute
                  address:
                     name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Joan Allalunis-Turner
            affiliation:
                  name:University of Alberta, Cross Cancer Institute
                  address:
                     name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:11
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Alberta, Cross Cancer Institute
      address:
         name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
         type:PostalAddress
      name:University of Alberta, Cross Cancer Institute
      address:
         name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
         type:PostalAddress
      name:University of Alberta, Cross Cancer Institute
      address:
         name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
         type:PostalAddress
      name:University of Alberta, Cross Cancer Institute
      address:
         name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jianxun Han
      affiliation:
            name:University of Alberta, Cross Cancer Institute
            address:
               name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
               type:PostalAddress
            type:Organization
      name:Ivy Ma
      affiliation:
            name:University of Alberta, Cross Cancer Institute
            address:
               name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
               type:PostalAddress
            type:Organization
      name:Michael J Hendzel
      affiliation:
            name:University of Alberta, Cross Cancer Institute
            address:
               name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Joan Allalunis-Turner
      affiliation:
            name:University of Alberta, Cross Cancer Institute
            address:
               name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
      name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
      name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
      name:Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada

External Links {🔗}(173)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.68s.

LINK . SPRINGER . COM {}